- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01114048
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM) (KMM-97)
September 21, 2011 updated by: Chonnam National University Hospital
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM) Who Are Eligible for Autologous Stem Cell Transplantation: Multicenter Phase 2 Study
In this study, the investigators will analyze the long-term outcomes of remission and survival, and identify those with primary resistant disease as more likely to benefit from CTD (thalidomide, cyclophosphamide, dexamethasone) and early intensification of Vel-CD (bortezomib and CD) as induction chemotherapy followed by autologous stem cell transplantation for the patients with newly diagnosed multiple myeloma.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study aims to assess the efficacy and toxicities of CTD and Vel-CD induction followed by high-dose therapy with autologous stem cell transplantation as a first line treatment for the patients with multiple myeloma.The investigators already investigated the thalidomide-based chemotherapy in patients with newly diagnosed MM.
The combined regimen consisted of cyclophosphamide, thalidomide and dexamethasone (CTD) for induction treatment.
CTD chemotherapy resulted in a favorable response with 79.4% overall response rate including 42.6% complete response (CR) or very good partial complete response (VGPR), and tolerable toxicity in MM patients.
Moreover, CTD chemotherapy did not affect the yield of the stem cell collection.The investigators also published that the clinical efficacy and safety of a four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was assessed for patients with relapsed or refractory multiple myeloma Vel-CTD chemotherapy.
Study Type
Interventional
Enrollment (Anticipated)
78
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Je-Jung Lee, M.D. and Ph.D.
- Phone Number: 82-61-3797638
- Email: drjejung@chonnam.ac.kr
Study Contact Backup
- Name: Deok-Hwan Yang, M.D. and Ph.D.
- Phone Number: 82-61-3797636
- Email: drydh1685@gmail.com
Study Locations
-
-
Jeollanam-do
-
Hwasun-gun, Jeollanam-do, Korea, Republic of, 519-809
- Recruiting
- Chonnam National University Hwasun Hospital
-
Principal Investigator:
- Je-Jung Lee, M.D. and Ph.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Newly diagnosed MM
- Aged between 18 and 65 years old
- With following measurable lesions (serum M-protein ≥ 1 g/dL or urine M-protein ≥ 400 mg/day, or free light chain ≥ 100 mg/L)
Exclusion Criteria:
- Smoldering or indolent myeloma
- ECOG performance status > 3 point
- Known hypersensitivity to cyclophosphamide, thalidomide or dexamethasone
- Peripheral neuropathy or neuropathic pain Grade 2 or higher as defined by NCI CTCAE version 3
- Uncontrolled or severe cardiovascular disease, including MI within 6 months of enrolment, NYHA Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis, cardiac ejection fraction <0.5 : Severe conduction disorder : Hypotension (sitting systolic BP ≤ 100 mmHg and/or sitting diastolic BP ≤ 60 mmHg
- Impaired hepatic function (AST or ALT ≥ x 3 upper normal, T-bilirubin ≥ x 2 upper normal)
- Creatinine clearance < 20 ml/min
- Corrected serum calcium ≥ 14 mg/dL
- Sepsis or current active infection
- Pregnancy or breast feeding
- Uncontrolled Diabetes Mellitus
- Previous history of Recurrent DVT or pulmonary embolism
- Active ulcers detected by gastroscopy
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- Receipt of extensive radiation therapy within 4 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
response rate for induction chemotherapy
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2010
Primary Completion (Anticipated)
March 1, 2012
Study Registration Dates
First Submitted
April 28, 2010
First Submitted That Met QC Criteria
April 29, 2010
First Posted (Estimate)
April 30, 2010
Study Record Updates
Last Update Posted (Estimate)
September 22, 2011
Last Update Submitted That Met QC Criteria
September 21, 2011
Last Verified
September 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Dexamethasone
- Cyclophosphamide
- Thalidomide
- Bortezomib
Other Study ID Numbers
- KMM-97
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Thalidomide, cyclophosphamide, dexamethasone, bortezomib
-
Millennium Pharmaceuticals, Inc.Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Completed
-
University of LeedsMerck Sharp & Dohme LLC; Celgene; AmgenUnknown
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)UnknownMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Grupo de Estudos Multicentricos em Onco-HematologiaCompletedMultiple Myeloma | Effects of Chemotherapy
-
Intergroupe Francophone du MyelomeJanssen Research & Development, LLC; HOVON - Dutch Haemato-Oncology AssociationActive, not recruitingMultiple MyelomaNetherlands, France, Belgium
-
Grupo de Estudos Multicentricos em Onco-HematologiaUnknown
-
Southwest Oncology GroupNational Cancer Institute (NCI)TerminatedMultiple MyelomaUnited States
-
European Myeloma NetworkEMN Research ItalyActive, not recruitingMultiple MyelomaCzechia, Greece, Italy
-
PETHEMA FoundationCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedChronic Renal Failure With Uremic NephropathyFrance